查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2003204

東莨菪鹼市場：2026-2032年全球市場預測（依品牌類型、劑型、應用、最終用戶及通路分類）

Hyoscine Market by Brand Type, Dosage Form, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，牛蒡市場價值將達到 4.8219 億美元，到 2026 年將成長到 5.0588 億美元，到 2032 年將達到 6.6806 億美元，複合年成長率為 4.76%。

主要市場統計數據
基準年 2025 4.8219億美元
預計年份：2026年 505,880,000 美元
預測年份 2032 6.6806億美元
複合年成長率 (%) 4.76%

簡要概述了莨菪鹼的臨床效用、其製劑的演變以及影響相關人員優先事項和戰略計劃的供應鏈趨勢。

東莨菪鹼在臨床上佔據獨特的地位，其應用範圍涵蓋預防暈動病、控制胃腸痙攣以及手術全期手術期分泌物。臨床醫師重視其抗膽鹼能作用，此作用能夠調節前庭和胃腸道通路。同時，製劑研發人員和生產商也不斷適應不斷變化的環境，包括給藥技術、監管環境和分銷通路趨勢。近年來，人們的關注點已從簡單的劑型轉向以患者為中心的、兼顧療效、耐受性和便利性的方案。

技術進步、更嚴格的監管以及分銷管道的變化如何重塑產品開發、商業模式和競爭優勢。

受技術進步、監管重點和醫療服務模式演變的驅動，東莨菪鹼市場格局正經歷變革性變化。新型經皮貼片的設計和長效注射劑的探索，反映了整個產業向緩釋和藥物安全檢測能夠提高患者的用藥依從性並減少全身性副作用。除了產品創新之外，監管機構也越來越重視生命週期資料、真實世界安全性監測和核准後監管，這迫使生產商加強對藥物警戒基礎設施和品質系統的投入。

為因應美國關稅措施，企業正在進行戰略供應鏈重組和採購調整，推動整個價值鏈的多元化、近岸外包和韌性增強。

美國2025年推出的關稅政策和貿易措施正給整個醫藥供應鏈帶來壓力，尤其是那些依賴進口活性成分和特殊包裝的產品。因此，製造商正在重新審視其籌資策略，力求在不影響產品品質或供應連續性的前提下，降低投入成本波動所帶來的風險。實際上，這正在加速推動原料藥（API）來源多元化、選擇替代供應商以及評估近岸外包方案，以降低跨境關稅風險。

將品牌策略、臨床應用、最終用戶需求、劑型偏好和分銷管道趨勢與商業性成功聯繫起來的實用細分見解。

精細的市場區隔方法清晰地揭示了臨床需求、製劑創新和商業性重點之間的交集。按品牌類型分析表明，品牌藥和學名藥之間的差異導致了不同的策略。品牌藥生產商專注於透過創新的給藥系統和全面的患者支援服務來實現差異化，而學名藥生產商則在成本、生產效率和分銷網路覆蓋範圍方面競爭。按應用領域分類，胃腸道疾病的治療和暈動病的預防之間存在差異，而處方醫生的特徵、給藥方案和製劑偏好等方面的差異決定了研發重點。

將美洲、歐洲、中東和非洲以及亞太地區影響監管路徑、供應鏈最佳化和商業化策略的區域趨勢進行比較。

區域趨勢對東莨菪鹼製劑的監管路徑、供應鏈決策和商業策略有顯著影響。在美洲，結構化的醫院系統和整合的支付機制正在促進實證醫學證據與處方集納入之間的緊密結合。同時，數位藥局的日益普及推動了消費者直接取得藥物和遠端醫療主導處方箋的持續成長。這種環境正在加速那些在提高用藥依從性和耐受性方面展現出顯著優勢的新製劑的快速推廣應用。

競爭格局分析，重點在於配方差異化、製造夥伴關係和分銷聯盟，這些因素決定了策略優勢。

在疥蟎生態系中，競爭定位取決於一系列能力，從專有配方技術到非專利藥生產，甚至包括與專用醫療設備的整合。原廠公司通常專注於緩釋技術、經皮貼片設計以及旨在促進處方醫生和支付方採用的綜合病患支援計畫。而非專利藥生產商則優先考慮規模化、成本效益高的生產方式以及快速的監管核准流程，以滿足基本的臨床需求，他們通常憑藉豐富的競標經驗和廣泛的分銷網路展開競爭。

東莨菪鹼相關人員面臨的實際策略挑戰：聚焦供應韌性、配方創新、實證實踐和整合通路最佳化

產業領導者應優先考慮一系列切實可行的舉措，使開發平臺與營運韌性和商業性執行力保持一致。首先，實現原料藥和關鍵組件來源多角化，以降低跨境關稅和物流衝擊的風險，同時加強對替代供應商的選擇和供應商管治。其次，加快對經皮和緩釋平台的投資，以提高患者依從性，並在通用口服片劑的基礎上形成差異化優勢，並輔以強力的臨床和人體工學證據。

採用穩健的混合研究途徑，結合與關鍵相關人員的訪談、監管文獻審查、專利分析和供應鏈情境規劃，以獲得可操作的見解。

本執行摘要的分析融合了第一手和第二手調查方法，旨在確保其相關性和可操作性。第一手研究包括對臨床醫生、採購經理、監管專家和生產主管進行結構化訪談，以了解當代決策者、挑戰和推廣障礙。第二手研究包括對監管指南、同行評審的臨床文獻、專利申請和產品標籤的審查，以闡明臨床背景和製劑趨勢。

將臨床需求、劑量創新和穩健的運作相結合，共同定義海索汀相關人員的成功軌跡。

東莨菪鹼的未來將受到臨床需求、給藥方式創新和供應鏈韌性三者交互作用的影響。儘管該化合物已確立的治療作用為其提供了穩定的基礎，但競爭優勢將越來越取決於相關人員如何有效地將製劑創新和循證醫學證據轉化為易於獲取且可靠的產品。隨著醫療服務模式向門診和以患者為中心的護理模式轉變，經皮和緩釋製劑因其在提高用藥依從性和耐受性方面的優勢，有望獲得更多關注。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：以品牌類型分類的海索汀市場

  • 品牌商品
  • 非專利的

第9章 以劑型分類的莨菪鹼市場

  • 注射液
  • 口服錠劑
  • 經皮貼劑

第10章：莨菪鹼市場：依應用領域分類

  • 消化器官系統疾病
  • 暈動病

第11章 莨菪鹼市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第12章 莨菪鹼市場：依通路分類

  • 線上
    • 行動應用
    • 僅限網路的入口網站
  • 離線
    • 醫院藥房
    • 零售藥房

第13章 西酞普蘭市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 莨菪鹼市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 霍斯汀市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國海索汀市場

第17章：中國海索汀市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Centroflora-Cms SA
  • Eli Lilly and Company
  • Fine Chemicals Corporation
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Lannett Company, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Strides Pharma Science Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-AD517FAAA7B7

The Hyoscine Market was valued at USD 482.19 million in 2025 and is projected to grow to USD 505.88 million in 2026, with a CAGR of 4.76%, reaching USD 668.06 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 482.19 million
Estimated Year [2026] USD 505.88 million
Forecast Year [2032] USD 668.06 million
CAGR (%) 4.76%

A concise orientation to hyoscine's clinical utility formulation evolution and supply chain dynamics shaping stakeholder priorities and strategic planning

Hyoscine occupies a distinct clinical niche that spans prevention of motion sickness to management of gastrointestinal spasm and perioperative secretions. Clinicians value the compound for its anticholinergic properties, which modulate vestibular and gastrointestinal pathways; formulators and manufacturers, meanwhile, are navigating an evolving landscape of delivery technologies, regulatory expectations, and channel dynamics. In recent years, attention has shifted from simple dose forms toward patient-centric options that balance efficacy with tolerability and convenience.

As clinical practice increasingly emphasizes outpatient care and home-based management, hyoscine's relevance in ambulatory settings has risen. Simultaneously, innovations in transdermal and controlled-release formulations respond to adherence challenges and profile improvements requested by prescribers. These forces create both opportunities and obligations for developers to demonstrate consistent product quality, robust pharmacovigilance, and alignment with evolving payer and hospital procurement priorities. Consequently, stakeholders must integrate clinical, commercial, and regulatory perspectives to maintain competitive positioning.

Transitioning from traditional supply chains to more resilient, diversified networks has become a strategic imperative. Manufacturers and distributors are recalibrating operations to ensure uninterrupted access to active pharmaceutical ingredient sources and packaging materials. This introductory overview frames the remainder of the executive summary by underscoring the interplay of therapeutic utility, formulation trends, and supply-side resilience that defines the current hyoscine landscape.

How technological advances regulatory tightening and shifts in distribution channels are reshaping product development commercial models and competitive advantage

The hyoscine landscape is undergoing transformative shifts driven by technology, regulatory focus, and changing care delivery models. Novel transdermal patch designs and long-acting injectable research reflect a broader industry pivot toward extended-release and non-oral delivery platforms that improve adherence and reduce systemic side effects. Parallel to product innovation, regulators are placing greater emphasis on lifecycle data, real-world safety monitoring, and post-approval surveillance, prompting manufacturers to invest in pharmacovigilance infrastructure and quality systems.

On the commercial side, distribution channels are fragmenting; digital pharmacy platforms have accelerated patient access and altered purchasing behavior, while hospital procurement remains decisive for in-hospital and perioperative uses. At the same time, consolidation among contract development and manufacturing organizations reshapes where and how hyoscine formulations are produced, encouraging vertical integration and strategic partnerships that can shorten time-to-market.

Collectively, these trends are transforming competitive dynamics from simple price competition to differentiated offerings that emphasize patient experience, regulatory robustness, and supply resiliency. Firms that align innovation with pragmatic regulatory and distribution strategies will be better positioned to capitalize on shifts in prescribing patterns and care delivery.

Strategic supply chain realignment and procurement responses to United States tariff measures driving diversification nearshoring and resilience initiatives across the value chain

Tariff policies and trade measures introduced by the United States in 2025 have exerted pressure across pharmaceutical supply chains, particularly for products reliant on imported active pharmaceutical ingredients and specialized packaging. The cumulative effect has been a recalibration of procurement strategies as manufacturers seek to mitigate input-cost volatility without compromising quality or continuity of supply. In practice, this has accelerated efforts to diversify API sourcing, qualify secondary suppliers, and evaluate nearshoring options that reduce exposure to cross-border tariff risk.

In addition, procurement teams within hospitals and integrated health systems have reacted by tightening contract terms and sharpening supplier evaluation criteria to account for potential cost pass-throughs. These dynamics have encouraged closer collaboration between commercial teams and supply-chain functions, fostering scenario planning that prioritizes supply continuity and contract flexibility. Meanwhile, regulatory and customs clearance complexities have encouraged manufacturers to enhance documentation and compliance capabilities, reducing the risk of shipment delays that could disrupt inventory-sensitive care settings.

Importantly, the tariff environment has also elevated the strategic value of packaging and delivery innovations that reduce weight or reliance on imported components. Companies investing in such incremental innovations can achieve greater insulation from trade-policy volatility. Overall, the 2025 tariff measures functioned as a catalyst for strategic supply-chain refinement, stronger supplier governance, and an intensified focus on resilience and operational agility.

Actionable segmentation insights linking brand strategy clinical application end-user requirements dosage form preferences and distribution channel dynamics to commercial success

A nuanced segmentation approach clarifies where clinical demand, formulation innovation, and commercial focus converge. When analyzed by brand type, distinctions between branded and generic offerings drive divergent strategies: branded manufacturers emphasize differentiation through novel delivery systems and enhanced patient-support services, whereas generic players compete on cost, manufacturing efficiency, and distribution breadth. Based on application, demand varies between gastrointestinal disorder management and motion sickness prevention, with differing prescriber profiles, dosing regimens, and formulation preferences informing development priorities.

Different end users shape procurement and usage patterns; clinics and hospitals require reliable supply, regulatory documentation, and often larger volume packaging, while home care settings prioritize ease of use, patient adherence, and convenient dispensing. Across dosage forms, injectable solutions remain critical for acute inpatient needs, oral tablets are the mainstay for outpatient prescriptions, and transdermal patches are gaining traction for sustained symptom control and improved tolerability. Distribution channels further influence market access: hospital pharmacies must navigate institutional formularies and group purchasing dynamics, online pharmacies drive convenience and direct-to-patient fulfillment, and retail pharmacies offer accessibility and pharmacist-led counseling. Each channel also has layered sub-segments that require tailored commercial and regulatory approaches to optimize uptake and patient outcomes.

Understanding these segmentation vectors enables companies to align R&D, regulatory submissions, and commercial tactics with the specific requirements and decision drivers of each customer cohort, thereby enhancing the probability of successful adoption and long-term retention.

Comparative regional dynamics shaping regulatory pathways supply chain optimization and commercialization strategies across the Americas Europe Middle East Africa and Asia Pacific

Regional dynamics materially affect regulatory pathways, supply-chain decisions, and commercial strategies for hyoscine products. In the Americas, structured hospital systems and integrated payer mechanisms encourage strong alignment between evidence generation and formulary inclusion, while digital pharmacy adoption continues to expand direct-to-consumer access and telehealth-driven prescribing. This environment favors rapid dissemination of new formulations that demonstrate measurable benefits in adherence or tolerability.

Within Europe Middle East & Africa, regulatory heterogeneity and variable reimbursement landscapes create both opportunities and complexities. Manufacturers must navigate diverse approval requirements and pricing mechanisms, often prioritizing key regulatory jurisdictions for initial launches while building clinical and health-economic dossiers to support broader access. Emerging markets in the region may offer cost-effective manufacturing and growing demand for essential medicines, but success depends on tailored distribution strategies and partnerships with regional distributors.

Asia-Pacific presents a mix of advanced biotech hubs and rapidly evolving healthcare infrastructures. High-capacity contract manufacturers and increasing local regulatory sophistication support accelerated product development and regional supply. Simultaneously, expanding outpatient care and consumer health awareness are driving demand for user-friendly dosage forms such as transdermal patches and oral formulations optimized for adherence. Across all regions, cross-border regulatory harmonization efforts and supply-chain diversification remain pivotal considerations for long-term commercial planning.

Competitive landscape analysis emphasizing formulation differentiation manufacturing partnerships and distribution collaborations that determine strategic advantage

Competitive positioning in the hyoscine ecosystem is defined by a spectrum of capabilities that range from proprietary formulation expertise to high-volume generic manufacturing and specialized device integration. Innovator firms typically focus on sustained-release technologies, transdermal patch design, and integrated patient-support programs that bolster adoption among prescribers and payers. Generic manufacturers emphasize scale, cost-efficient production, and rapid regulatory pathways to meet baseline clinical demand, often competing on tender performance and distribution reach.

Contract development and manufacturing organizations play a pivotal role by enabling both small innovators and large generics to scale production while maintaining quality compliance. Strategic partnerships with medical-device specialists are increasingly important for transdermal and combination product development, where device performance and human factors design materially affect outcomes. Additionally, distributors and digital pharmacy platforms are emerging as influential go-to-market partners, offering direct channels to patients and alternative fulfillment models that can shorten time-to-treatment.

For companies operating in this space, competitive advantage derives from an integrated approach that combines robust regulatory evidence, manufacturing reliability, and differentiated delivery modalities. Firms that bridge these competencies with effective channel strategies will be better positioned to respond to evolving prescriber expectations and payer demands.

Practical strategic imperatives for hyoscine stakeholders focusing on supply resilience formulation innovation evidence generation and integrated channel optimization

Industry leaders should prioritize a set of pragmatic actions that align development pipelines with operational resilience and commercial execution. First, diversify API and critical component sourcing to reduce exposure to cross-border tariff and logistical shocks while qualifying redundant suppliers and strengthening supplier governance. Second, accelerate investment in transdermal and controlled-release platforms that improve patient adherence and create differentiation beyond commodity oral tablets, supported by robust clinical and human factors evidence.

Third, deepen engagement with hospital formulary committees and payers by generating real-world evidence and health-economic analyses that demonstrate value in targeted use cases. Fourth, integrate digital channels into commercial models to capture direct-to-patient demand and facilitate adherence programs, thereby enhancing patient outcomes and data capture. Fifth, establish flexible manufacturing arrangements through partnerships with CDMOs and device specialists to scale quickly in response to demand shifts while maintaining compliance with regulatory expectations.

By executing these priorities in parallel, organizations can reduce operational risk, increase the market relevance of their portfolios, and create defensible differentiation that resonates with clinicians, payers, and end users.

Robust mixed methods research approach combining primary stakeholder interviews regulatory literature review patent analysis and supply chain scenario planning for actionable insights

The analysis underpinning this executive summary synthesizes primary and secondary research methods designed to ensure validity and practical relevance. Primary inputs included structured interviews with clinicians, procurement leaders, regulatory experts, and manufacturing executives to capture contemporary decision drivers, pain points, and adoption thresholds. Secondary research comprised review of regulatory guidelines, peer-reviewed clinical literature, patent filings, and product labeling to establish clinical context and formulation trends.

Complementary analyses incorporated supply-chain mapping and scenario planning to assess the implications of trade and tariff changes, as well as a review of technology adoption patterns in delivery systems and digital distribution. Data integrity protocols included cross-verification of interview insights with documented regulatory and clinical sources, and triangulation across multiple stakeholder perspectives to reduce bias. This mixed-methods approach ensures that the findings are grounded in current practice and can inform pragmatic strategic decisions for developers, manufacturers, and commercial teams.

Synthesis of how clinical demand delivery innovation and resilient operations collectively define success trajectories for hyoscine stakeholders

Hyoscine's future will be shaped by an interplay of clinical needs, delivery innovation, and supply-chain resilience. The compound's established therapeutic roles provide a stable foundation, yet competitive advantage will increasingly depend on how effectively stakeholders translate formulation innovation and evidence generation into accessible, reliable products. As healthcare delivery shifts toward outpatient and patient-centered care, transdermal and sustained-release options are poised to capture attention for their adherence and tolerability benefits.

Concurrently, geopolitical and trade developments have highlighted the necessity of diversified sourcing and flexible manufacturing arrangements. Companies that anticipate procurement disruptions and align commercial strategies with regulatory and payer expectations will sustain access and relevance. In sum, success in the hyoscine space requires integrated execution across R&D, manufacturing, regulatory, and commercial functions to deliver differentiated, reliable therapeutics that meet evolving clinician and patient needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hyoscine Market, by Brand Type

  • 8.1. Branded
  • 8.2. Generic

9. Hyoscine Market, by Dosage Form

  • 9.1. Injectable Solution
  • 9.2. Oral Tablets
  • 9.3. Transdermal Patch

10. Hyoscine Market, by Application

  • 10.1. Gastrointestinal Disorders
  • 10.2. Motion Sickness

11. Hyoscine Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Hyoscine Market, by Distribution Channel

  • 12.1. Online
    • 12.1.1. Mobile App
    • 12.1.2. Web Only Portal
  • 12.2. Offline
    • 12.2.1. Hospital Pharmacy
    • 12.2.2. Retail Pharmacy

13. Hyoscine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hyoscine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hyoscine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Hyoscine Market

17. China Hyoscine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. B. Braun Melsungen AG
  • 18.7. Baxter International Inc.
  • 18.8. Bayer AG
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. Centroflora-Cms S.A.
  • 18.11. Eli Lilly and Company
  • 18.12. Fine Chemicals Corporation
  • 18.13. Fresenius Kabi AG
  • 18.14. GlaxoSmithKline plc
  • 18.15. Hikma Pharmaceuticals PLC
  • 18.16. Johnson & Johnson
  • 18.17. Lannett Company, Inc.
  • 18.18. Merck & Co., Inc.
  • 18.19. Mylan N.V.
  • 18.20. Novartis AG
  • 18.21. Perrigo Company plc
  • 18.22. Pfizer Inc.
  • 18.23. Roche Holding AG
  • 18.24. Sanofi S.A.
  • 18.25. Strides Pharma Science Ltd.
  • 18.26. Sun Pharmaceutical Industries Ltd.
  • 18.27. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HYOSCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HYOSCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HYOSCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HYOSCINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HYOSCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HYOSCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HYOSCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HYOSCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HYOSCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HYOSCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HYOSCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HYOSCINE MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HYOSCINE MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HYOSCINE MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HYOSCINE MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HYOSCINE MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HYOSCINE MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HYOSCINE MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HYOSCINE MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HYOSCINE MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HYOSCINE MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HYOSCINE MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HYOSCINE MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HYOSCINE MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HYOSCINE MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HYOSCINE MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HYOSCINE MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HYOSCINE MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HYOSCINE MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HYOSCINE MARKET SIZE, BY MOTION SICKNESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HYOSCINE MARKET SIZE, BY MOTION SICKNESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYOSCINE MARKET SIZE, BY MOTION SICKNESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HYOSCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HYOSCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HYOSCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HYOSCINE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HYOSCINE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HYOSCINE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HYOSCINE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HYOSCINE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HYOSCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HYOSCINE MARKET SIZE, BY MOBILE APP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HYOSCINE MARKET SIZE, BY MOBILE APP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HYOSCINE MARKET SIZE, BY MOBILE APP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HYOSCINE MARKET SIZE, BY WEB ONLY PORTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HYOSCINE MARKET SIZE, BY WEB ONLY PORTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HYOSCINE MARKET SIZE, BY WEB ONLY PORTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HYOSCINE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HYOSCINE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HYOSCINE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HYOSCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS HYOSCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HYOSCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 131. GCC HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GCC HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 134. GCC HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. GCC HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GCC HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 155. G7 HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. G7 HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 158. G7 HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. G7 HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. G7 HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 162. G7 HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. NATO HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NATO HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 166. NATO HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NATO HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. NATO HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. NATO HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 170. NATO HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES HYOSCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA HYOSCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA HYOSCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA HYOSCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA HYOSCINE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)